RU11

RU11. It is a synthetic small molecule compound that has garnered significant interest within the fields of medicinal chemistry and molecular biology for its targeted biological activity. Initially identified through high-throughput screening efforts, its development has been pursued by several biotechnology firms and academic laboratories, notably in the context of oncology and neurodegenerative disease research. The compound's mechanism of action involves selective modulation of specific protein-protein interactions or enzyme pathways, making it a valuable tool for probing cell signaling networks and a potential candidate for therapeutic intervention.

Overview

The discovery of RU11 can be traced to collaborative work between researchers at Scripps Research and the Broad Institute, where it was flagged for its unique pharmacophore profile in a library screen against a kinase target. Its proprietary structure is closely guarded, but it is known to belong to a class of heterocyclic compounds designed for optimal bioavailability and blood-brain barrier penetration. Early studies, published in journals like Nature Chemical Biology and the Journal of Medicinal Chemistry, highlighted its potency in in vitro assays and established a foundation for subsequent preclinical investigation. The intellectual property surrounding RU11 is held by Vertex Pharmaceuticals, which has led its primary commercial development.

Chemical Properties

RU11 is characterized as a low-molecular-weight organic compound with a core structure based on a substituted indole or quinazoline scaffold, a common feature in many FDA-approved drugs. Analytical data from nuclear magnetic resonance spectroscopy and mass spectrometry confirm the presence of key functional groups, including a sulfonamide linkage and a fluorine atom, which are critical for its binding affinity and metabolic stability. Its log P value suggests moderate lipophilicity, and it exhibits good solubility in dimethyl sulfoxide and certain aqueous buffer systems at physiological pH. The compound's stereochemistry is defined, with its active form being a single enantiomer produced via asymmetric synthesis.

Applications

The primary application of RU11 is as a chemical probe to investigate the role of specific phosphatase or deubiquitinase enzymes in disease models, particularly in glioblastoma and Alzheimer's disease. In cancer research, it has shown efficacy in sensitizing chemotherapy-resistant cell lines derived from pancreatic cancer patients in studies conducted at the MD Anderson Cancer Center. Furthermore, its neuroprotective effects have been demonstrated in transgenic mouse models of tauopathy, reducing pathological protein aggregation. Beyond biomedical research, derivatives of RU11 have been explored in agricultural chemistry for their potential as plant growth regulators in collaborations with Syngenta.

Research and Development

Ongoing clinical trials for RU11 are currently in Phase I/II, sponsored by Genentech, focusing on its safety and pharmacokinetics in patients with advanced solid tumors. Parallel research at Harvard University and the Stanford University School of Medicine utilizes cryo-electron microscopy and X-ray crystallography to elucidate its precise molecular interactions with targets like the PTEN protein. Significant efforts are also directed at structure-activity relationship studies to improve its therapeutic index and reduce potential off-target effects. Funding for this work has been provided by grants from the National Institutes of Health and the Cancer Research Institute.

Safety and Regulation

As an investigational new drug, RU11 is subject to stringent guidelines set by the U.S. Food and Drug Administration and the European Medicines Agency. Preclinical toxicology studies in Sprague-Dawley rats and beagle dogs indicated a manageable safety profile, with reversible hepatotoxicity observed only at high doses. Its Material Safety Data Sheet classifies it as a hazardous substance, requiring handling in accordance with Occupational Safety and Health Administration standards in laboratory settings. Environmental fate assessments, guided by the Environmental Protection Agency, are ongoing to evaluate its biodegradation potential and ecotoxicity.

Category:Chemical compounds Category:Experimental drugs